Good news! Expert consensus on the clinical application of donor-derived cell-free DNA detection in kidney transplantation (2022 version) is officially online

Recently, the "Expert Consensus on the Clinical Application of Donor-derived Cell-free DNA Detection in Kidney Transplantation" (2022 Edition) was officially released online in the Chinese Journal of Transplantation.

This consensus was co-written, discussed and finalized by 28 experts in the field of transplantation from 20 domestic organ transplantation centers. It brings together clinical application experience in the fields of different organ transplantation, pediatric transplantation, rejection, and BK virus-related kidney disease diagnosis and treatment, laying a solid foundation for the expanded application of donor-derived cfDNA in the field of transplantation.

Donor-derived cfDNA testing in China has gone from emergence and debate to a preliminary clinical application consensus over nearly five years. AlloDx is among the early companies in China to perform organ transplant donor-derived cell-free DNA testing, and has publicly published evidence on dd-cfDNA testing methodology, providing technical and data support for the development of donor-derived cfDNA application in domestic transplantation.

Consensus link: https://zhyzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.1674-3903.2022.05.001